Israeli Firm Matiself Targets 2027 Human Trials for Spinal Cord Implants

Israeli Startup Matiself Develops 3D Neural Implants for Spinal Cord Regeneration

While billionaires like Elon Musk focus on bypassing nervous system damage using digital chips through companies like Neuralink, an Israeli biotechnology firm is pursuing a fundamentally different approach. Founded in 2019 by Prof. Tal Dvir and Dr. Alon Sinai, Matiself is developing NewRal, an innovative neural implant designed to treat traumatic spinal cord injuries by biologically restoring the damaged tissue itself.

Lab-Grown Living Tissue and Animal Trials

The technology relies on harvesting blood and fat tissue from the patient to engineer a personalized, three-dimensional neural implant in a laboratory setting. This living tissue is designed to integrate seamlessly into the injury site, bridging the gap to renew neural communication between the brain and the rest of the body. Preclinical results published in 2022 by Tel Aviv University researchers showed that approximately 80% of animals suffering from chronic paralysis regained the ability to walk after receiving the engineered tissue implant.

Upcoming Clinical Trials and Nasdaq Plans

Building on these promising animal studies—which included a 248-subject safety evaluation—Matiself is now preparing for its first human clinical trials, slated for 2027. The initial phase will focus on safety for patients with complete and chronic thoracic spinal cord injuries. To support these trials, the company is targeting a dual listing on the Nasdaq exchange during the first half of 2027.

"We are moving toward one of the central milestones in Matiself's development plan: the first clinical trial in humans," stated CEO Gil Hakim.

While financing challenges remain and the technology still needs to prove its efficacy in humans, Matiself's biological approach offers a revolutionary potential horizon for victims of accidents and war injuries.